Previous 10 |
ORLANDO, Fla., Oct. 28, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage oncology biopharmaceutical company focused on the development therapies f...
ORLANDO, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late-stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inf...
ORLANDO, Fla., Sept. 26, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of immunomodulating therapies for the treatment of a...
ORLANDO, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development i...
Immune Therapeutics Inc Urges Shareholders to Vo te Yes and Support the Company's Three Proposals ORLANDO, FL / ACCESSWIRE / September 17, 2019 / Immune Therapeutics, Inc. ( OTC PINK:IMUN) ("Immune," "IMUN" or the "Company"), a clinical late stage biopha...
ORLANDO, Fla., Sept. 10, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment ...
ORLANDO, Fla., May 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, infl...
News, Short Squeeze, Breakout and More Instantly...
Orlando, FL, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp (OTC Pink: IMUN) (“Biostax”), a hub and spoke biotech development engine, sadly announces the passing of H. Louis Salomonksy, a dedicated member of its Board of Directors. Mr. Salomonksy pas...
Orlando, FL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp . (OTC Pink: IMUN) (“Biostax”), a hub-and-spoke biotech development engine, announces the signing of a research collaboration agreement with Immgenuity, Inc . The joint resear...
Orlando, FL, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) ("Biostax"), a hub-and-spoke biotech development engine, announces that they have accepted the transfer of three Investigational New Drug Applications (IND) for the drug candidate, JKB-12...